See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox<\/a><\/p>\nAt the time of writing, NRIX stock was up nearly 70% but had shed some premarket gains, trading 50% higher and remaining the top gainer among equities on Stocktwits.<\/p>\n
Roche will pay Nurix $700 million up front, with up to $1.6 billion in future payouts if certain development, regulatory, and sales milestones are achieved. The companies will share drug development costs in a 60:40 ratio, with Roche assuming the larger share of the expense, and profits will be split equally between the two.<\/p>\n
Nurix and Roche will tag-team and commercialize bexobrutideg in the United States. Outside the U.S., Roche will take over those same duties and pay Nurix a percentage of sales royalties ranging in the low to high teens.<\/p>\n
The transaction is expected to close in the third quarter this year.<\/p>\n
Nurix\u2019s bexobrutideg is aimed at treating, among other things, chronic lymphocytic leukaemia, a type of blood cancer that has a characteristic of recurring in patients even after initial treatment.<\/p>\n
The therapy has the potential to tap into a $41 billion market, and studies suggest it could become the most effective treatment option, with greater tolerability than existing drugs.<\/p>\n
\u201cWe believe bexobrutideg could represent a major leap forward in the fight against complex blood cancers and other diseases. We are proud to join forces with Nurix to accelerate these potential breakthroughs,\u201d said Levi Garraway, Roche\u2019s chief medical officer and head of global product development.<\/p>\n
On Stocktwits, retail sentiment about the NRIX stock remained in \u2018bullish\u2019 territory over the last 24 hours amid \u2018high\u2019 message volumes. One user on the platform thinks the stock has more room to run.<\/p>\n","protected":false},"excerpt":{"rendered":"Roche will pay Nurix $700 million up front, with up to $1.6 billion in future payouts if certain…\n","protected":false},"author":2,"featured_media":79457,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[471,41320,324,17290,41221,134],"class_list":["post-79456","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-blood-cancer","tag-chronic-lymphocytic-leukaemia","tag-drug-development","tag-initial-treatment","tag-nurix-therapeutics","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116714149348835401","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/79456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=79456"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/79456\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/79457"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=79456"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=79456"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=79456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}